Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized...

Area of Science:

• Cardiovascular Medicine
• Infectious Disease Prevention
• Clinical Trials

Background:

• Observational studies suggest pneumococcal polysaccharide vaccination (PPV) may protect against atherosclerosis.
• No randomized clinical trials have previously investigated PPV's effect on cardiovascular events.

Purpose of the Study:

• To determine if pneumococcal vaccination (PPV23) reduces the composite outcome of fatal/nonfatal acute coronary syndrome and ischemic stroke.
• To assess PPV23's efficacy in individuals at increased cardiovascular disease risk.

Main Methods:

• A double-blind, placebo-controlled, randomized clinical trial involving 4725 participants aged 55-60 with cardiovascular risk factors.
• Participants received either PPV23 or a placebo, with follow-up for 7 years.
• Primary outcome: composite of myocardial infarction or ischemic stroke, analyzed using competing risk models.

Main Results:

• No significant difference in the primary outcome between the PPV23 group (58 events) and the placebo group (64 events).
• Hazard ratio for the primary outcome was 0.90 (95% CI, 0.63-1.28; P=.57).
• Exploratory outcomes, including all-cause mortality and hospitalizations, also showed no significant differences. Study was underpowered due to lower than expected event rates.

Conclusions:

• PPV23 did not demonstrate a significant reduction in acute coronary syndrome or ischemic stroke rates in this trial.
• The study's findings are limited by insufficient statistical power.
• Further investigation into PPV's cardiovascular benefits is warranted.